Baker McKenzie legal advisor to Vicore Pharma in directed new share issue of USD 48 million

Vicore Pharma Holding AB has carried out a directed new share issue of shares of approximately USD 48 million where the subscription price was set through an accelerated bookbuilding procedure.

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The Company’s lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. The Company is publicly listed on the Nasdaq Stockholm exchange (VICO).

Jefferies GmbH and Pareto Securities AB acted as Joint Global Coordinators and Joint Bookrunners while Cantor Fitzgerald & Co. acted as Joint Bookrunner. Baker McKenzie acted as legal advisor to Vicore Pharma with an international capital markets team consisting of Henric Roth, Olof Larsson and Thea Hanson in Stockholm as well as Adam Farlow and Charles Farnsworth in London.